The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

Surprising research strongly suggests semaglutide can help fight substance use disorder. Why aren't we using it?

Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company accelerating the next ...

Novo Nordisk has set a minimum target of 25% weight loss in the trial, which would make CagriSema the most effective ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were mostly higher early Tuesday after the Biden administration proposed a rule that would allow Medicare ...

The "Type 2 Diabetes - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 75+ companies and 80+ pipeline drugs ...

The "Diabetes - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Diabetes - Pipeline Insight, 2024" report provides comprehensive insights about 200+ ...

“Especially in the ones for the GLP (Glucagon-like Peptide) analogue space, that’s one of the complex generics that Orbicular ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

Novo Nordisk is testing a Wegovy follow-up called CagriSema, based on semaglutide and amylin analogue cagrilintide, in phase 3, while Lilly has a triple agonist targeting GLP-1, GIP and glucagon ...